Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03613506
Other study ID # HBCCS AB-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 25, 2019
Est. completion date December 25, 2022

Study information

Verified date January 2022
Source Wuhan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project aims to investigate the relationship between radiation-induced the relationship between elevated peripheral blood TGFβ and complications of radiotherapy,and to analysis of changes in peripheral blood TGFβ levels after abdominal radiotherapy and its relationship with radiotherapy complications.Simultaneously,Patients who underwent abdominal radiotherapy were given captopril (sustained release) to block TGFβ,Whether it can reduce peripheral blood TGFβ levels and reduce radiotherapy complications,to explore the protective effect of blocking TGFβ secretion on normal tissues after radiotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 226
Est. completion date December 25, 2022
Est. primary completion date June 25, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Informed consent form for this study has been signed 2. Age 18-70 years old, gender is not limited,Pathological diagnosis of patients with advanced malignant tumors,Radiotherapy indications; 3. BED (a/ß=10)=50;ECOG score 0-2;Blood routine:WBC=3.5×109/L,GRAN=2.0×109/L,Hb=90g/L,PLT=100×109/L; 4. Liver function: ALT or AST = 2.5 times the normal high value (ULN);Bilirubin = 1.5 × ULN, serum APK = 2.5 × ULN; 5. Renal function:Serum creatinine =1.5×ULN, and creatinine clearance =60ml/min 6. No organ transplant history 7. Women of childbearing age must undergo a urine pregnancy test within 7 days prior to initiation of treatment and the results are negative and not in lactation 8. Male and female patients of childbearing age agreed to adopt a reliable method of contraception before entering the trial and during the study until 30 days after stopping the drug. Exclusion Criteria: 1. Patients undergoing chemotherapy or targeted therapy at the same time 2. Long-term use of ACEI or ARB drugs for hypertension 3. This radiotherapy site has been treated with radiotherapy;Combined with severe heart disease or major organ failure 4. Have a history of drug abuse or alcohol addiction 5. Combined active infection 6. Combined with severe malnutrition or severe anemia 7. Human immunodeficiency virus (HIV) infection 8. During pregnancy or lactation 9. Those who are unable to tolerate or may be allergic to the drugs used in this study;Persons without civil capacity or limited capacity for civil conduct; 10. Researchers believe that it is not suitable for inclusion

Study Design


Intervention

Drug:
Captopril 12.5 Mg
Taking captopril 12.5mg b.i.d for two months before radiotherapy.

Locations

Country Name City State
China Jin Peng Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Wuhan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Study the effect of abdominal radiation therapy on peripheral blood TGFß levels The levels of TGF-ß in peripheral blood of patients before and after radiotherapy were compared. 12 weeks
Primary Blocking TGFß for protective effect on normal tissues Give two groups of patients captopril (sustained release) 12.5mg b.i.d. for two months,comparing their levels of TGF-ß in peripheral blood 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT05543239 - Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Radiotherapy-Related Neuropathic Pain N/A
Terminated NCT04535908 - Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older. N/A
Recruiting NCT04115267 - Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies
Recruiting NCT05820633 - Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer. N/A
Completed NCT05880446 - PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ) N/A
Recruiting NCT05724004 - Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB) N/A
Recruiting NCT04612907 - Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer N/A
Recruiting NCT05762900 - Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients Phase 2
Completed NCT06353724 - Comparison Between the Effect of Using Conventional and Digital Oral Positional Radiation Stent N/A
Not yet recruiting NCT05548504 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC Phase 2
Recruiting NCT05224297 - Patient Experience Data in Radiation Oncology
Recruiting NCT05776147 - Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study
Completed NCT04842409 - Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery
Recruiting NCT03742687 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC N/A
Not yet recruiting NCT05614700 - Prostate Reirradiation Toxicity Outcomes Feasibility Study N/A
Completed NCT04027543 - Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma(NewEC Study)
Recruiting NCT05354596 - A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY). N/A
Recruiting NCT03378856 - Evaluation of Technological Innovation in Radiotherapy
Recruiting NCT03343236 - Nutrition and Inflammation in Patients With Head and Neck Cancer